KR960006924A - Diltiazem sustained release formulation - Google Patents
Diltiazem sustained release formulation Download PDFInfo
- Publication number
- KR960006924A KR960006924A KR1019940019516A KR19940019516A KR960006924A KR 960006924 A KR960006924 A KR 960006924A KR 1019940019516 A KR1019940019516 A KR 1019940019516A KR 19940019516 A KR19940019516 A KR 19940019516A KR 960006924 A KR960006924 A KR 960006924A
- Authority
- KR
- South Korea
- Prior art keywords
- diltiazem
- pharmacologically acceptable
- sustained release
- water
- polymer
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 딜티아젬 또는 약리적으로 허용되는 그 염을 함유하는 1일 1회 복용의 틸티아젬의 서방성 제형에 관한 것으로, 구형 코어; 이 구형 코어에 코팅되는 딜티아젬, 결합제 및 딜테아젬과 이온결합이 가능한 약리학상 허용되며 장관의 생리적 pH에서 음전하를 가지는 고분자로 이루어진 혼합 약물층;이 약물함유층 외부에 1층 이상의 다중막으로 수용성 혹은 수불용성 폴리머의 단독 또는 혼합물의 멤브레인층으로 이루어진다.The present invention relates to a sustained release formulation of tiltiazem once daily containing diltiazem or a pharmacologically acceptable salt thereof, comprising: a spherical core; Pharmacologically acceptable pharmacologically acceptable mixed drug layer capable of ion bonding with diltiazem, a binder, and dilteaze coated on the spherical core; a mixed drug layer consisting of a negatively charged polymer at the physiological pH of the intestine; It consists of a membrane layer of singly or a mixture of water-soluble or water-insoluble polymers.
본 발명은 딜티아젬의 짧은 반감기와 빠른 흡수로 인해 약효유지시간이 짧아져 자주 복용해야 하는 단점을 보완하고 고단위 처방에 의해 높은 유효 혈중농도를 유지시켜서 협십증 및 중증 고혈압과 같은 환자로 하여금 1일1회 복용으로도 충분한 약효를 유지할 수 있게 하며, 단일한 펠렛으로 간단히 제조되는 신규 서방성 펠렛을 제공한다.The present invention shortens the drug retention time due to the short half-life and rapid absorption of diltiazem, thereby compensating for the disadvantages of frequent intake and maintaining high effective blood concentrations by high-prescription therapy, thereby allowing patients such as angina and severe hypertension. It is possible to maintain sufficient medicinal effects even once a day, and to provide novel sustained release pellets which are simply prepared into a single pellet.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019940019516A KR960006924A (en) | 1994-08-08 | 1994-08-08 | Diltiazem sustained release formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019940019516A KR960006924A (en) | 1994-08-08 | 1994-08-08 | Diltiazem sustained release formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
KR960006924A true KR960006924A (en) | 1996-03-22 |
Family
ID=66697659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940019516A KR960006924A (en) | 1994-08-08 | 1994-08-08 | Diltiazem sustained release formulation |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR960006924A (en) |
-
1994
- 1994-08-08 KR KR1019940019516A patent/KR960006924A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100535319B1 (en) | Drug composition with controlled drug release rate | |
EP0226884B1 (en) | System for the controlled-rate release of active substances | |
TW577758B (en) | Intra-articular preparation for the treatment of arthropathy | |
US6417227B1 (en) | Methods of delivery of cetyl myristoleate | |
NZ263632A (en) | Oral sustained release morphine composition having a barrier coating comprising at least one water insoluble compound | |
US20080069848A1 (en) | Device, method, and use for treatment of neuropathy involving nitric oxide | |
KR930003905A (en) | Pharmaceutical binding agents | |
PL142312B1 (en) | Process for preparing delayed-action preparation with bromohexyne | |
DE60036874D1 (en) | PELLET FORMULATION WITH CONTROLLED RELEASE | |
SK284135B6 (en) | Percutaneous delivery system | |
LV12399A (en) | Enhanced once-a-day pulse minicyclic mini-cycling systems | |
JP2000506133A (en) | Nitric oxide donor can reduce drug-induced toxicity | |
WO1995029666A1 (en) | Sustained-release pharmaceutical system for the delivery of antioxidants | |
EP0136103B1 (en) | Amosulalol hydrochloride long acting formulations | |
KR850700212A (en) | Sustained Release Pharmaceutical Wexel | |
JPH0733682A (en) | Novel composite material and sustained-release preparation in which the same material is used as carrier | |
JPH02501982A (en) | Compositions of polymeric diffusion matrices for transdermal administration of pharmaceutical formulations | |
KR960006924A (en) | Diltiazem sustained release formulation | |
CA2881726A1 (en) | Extended release compositions of an aminoalkyl nitrate | |
KR910007517A (en) | Sustained-release preparations of basic pharmaceutical hydrochloride | |
GB2190287A (en) | Oral ketoprofen formulation | |
JPH0688901B2 (en) | Liquid long-term release pharmaceutical composition containing ionic drug | |
JPH07500332A (en) | Novel drug with ion exchanger | |
Naval | Formulation and evaluation of floating microspheres of captopril for prolonged gastric residence time | |
WO2016197042A1 (en) | Modified or targeted release formulations of linaclotide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |